<DOC>
	<DOCNO>NCT01083485</DOCNO>
	<brief_summary>The purpose study demonstrate treatment OXN PR tablet non inferior treatment OXY PR tablet term analgesic efficacy patient postoperative pain knee arthroplasty base average pain intensity score .</brief_summary>
	<brief_title>OXN PR Compared OXY PR Subjects With Postoperative Pain After Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Males females 18 75 year age . Body mass index ( BMI ) 18 35 kg/m2 . If female le one year postmenopausal : negative serum urine pregnancy test ( positive betahuman chorionic gonadotrophin test ) screening . use adequate highly effective method contraception throughout study . A highly effective method contraception define one failure rate le 1 % per year use consistently correctly . Examples include sterilisation , implant , injectables , combine oral contraceptive , hormonal intra uterine device , sexual abstinence vasectomise partner . Confirmed diagnosis osteoarthritis knee . Planned surgical arthroplasty one knee . Planned postoperative epidural analgesia approximately 48 hour . Anticipated requirement daily opioid treatment epidural analgesia 2.5 day . Able participate study give write informed consent . Females pregnant lactating . Opioid use within 3 month start screen period . Stable treatment analgesic World Health Organisation ( WHO ) Step I ( nonopioid analgesic ) allow . History laxative use treat constipation within 3 month start screen period . History chronic constipation . Concurrent rheumatoid arthritis . Planned bilateral arthroplasty revision knee arthroplasty . History moderate severe hepatic impairment . History moderate severe respiratory depression hypoxia hypercapnia , chronic obstructive pulmonary disease , cor pulmonale , bronchial asthma , severe impairment pulmonary function . History uncontrolled hypothyroidism , Addison 's disease ( adrenal cortical insufficiency ) , psychosis , cholelithiasis , prostatic hypertrophy ( document residual 100 ml voiding ) , delirium tremens , pancreatitis , hypotension , uncontrolled hypertension , uncontrolled cardiovascular disease , head injury , epileptic disorder predisposition convulsion , treatment monoamine oxidase inhibitor ( concurrent within 2 week discontinuation ) . Contraindication treatment opioids . History hypersensitivity oxycodone , naloxone , excipients OXN PR tablet . History nonopioid induce paralytic ileus . Previous current history drug abuse , include alcohol abuse opioid abuse . Evidence clinically unstable disease Receipt investigational medicinal product within 30 day start screen period . Galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . Delayed gastric emptying . Severe renal impairment ( i.e . creatinine clearance &lt; 10 mL/minute ) . Weight &lt; 50 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Oxycodone</keyword>
	<keyword>Naloxone</keyword>
	<keyword>Postoperative pain</keyword>
	<keyword>Arthroplasty</keyword>
	<keyword>Efficacy</keyword>
</DOC>